We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Consortium for Analytic Standardization in Immunohistochemistry (IHC) Launched to Improve Patient IHC Test Accuracy

By LabMedica International staff writers
Posted on 11 Mar 2022
Print article
Image: IHC staining controls (Photo courtesy of Boston Cell Standards)
Image: IHC staining controls (Photo courtesy of Boston Cell Standards)

Standard patient blood tests can be analyzed in any lab and yield the same results every time because of international reference standards that ensure all tests are aligned with one another; both patient and physician can have confidence in the results wherever the tests are performed. No such reference standards exist in immunohistochemistry (IHC), meaning that different labs could – and often do – return different results from the same sample. Now, a newly-launched organization, the Consortium for Analytic Standardization in Immunohistochemistry (CASI), aims to improve patient IHC test accuracy and reproducibility.

CASI, launched by Boston Cell Standards (Boston, MA, USA), is led by an international panel of pathologists and scientists, with a mission to integrate analytic reference standards into IHC, a test format widely used in surgical pathology to evaluate cancers in tissue samples and determine correct treatment. Boston Cell Standards has invented the first and only IHC reference materials, including calibrators for IHC standardization and controls for daily verification of IHC assay accuracy. These tools incorporate concentration measures that are traceable to a National Institute of Standards and Technology (NIST) standard.

Rates of clinically inadequate IHC testing are roughly 10 times that of clinical blood testing labs, with test discrepancy rates of 10% to 30%. Introducing reference standards will raise the quality of IHC testing by giving pathologists certainty that their results are accurate and oncologists greater confidence in patient diagnosis and treatment selection. CASI will conduct studies to determine appropriate analytic sensitivity thresholds for selected IHC tests, publish the data it collects, and then offer analytic sensitivity recommendations. In addition to guiding routine clinical practice, these recommendations will be intended to facilitate and simplify methodology transfer between laboratories, from published literature, and in clinical trials.

“Biopsy testing in the pathology lab with immunohistochemistry is essential to characterizing a patient’s cancer and determining the proper course of treatment. However, a lack of industry-wide standards, calibrators and controls, and traceable units of measure has, for years, frustrated attempts to lower the error rate. It holds the entire field of pathology back,” said Dr. Steve Bogen, CEO of Boston Cell Standards, a board-certified clinical pathologist. “Building analytic standards and integrating them into routine clinical practice and clinical research will provide pathologists and clinical research scientists vital tools to inform their best work.”

“Harmonization among all IHC laboratories is an essential goal for improved patient care. The ability to set objective, quantitative lower limits of detection for any assay is a much-needed step in this direction,” said Dr. Emina Torlakovic, a board-certified anatomic and clinical pathologist and hematopathologist; director of Canadian Biomarker Quality Assurance academic program; division head of Hematopathology, Dept. of Pathology & Laboratory Medicine, Saskatchewan Health Authority and University of Saskatchewan; and, chairperson of the CASI steering committee. “The consortium’s work stands to make a valuable and lasting positive impact on labs, clinicians and patients, and improve the delivery of care. I’m honored to be a part of it.”

Related Links:
Boston Cell Standards 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.